Granite Investment Partners LLC raised its holdings in shares of Celgene Co. (NASDAQ:CELG) by 26.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,870 shares of the biopharmaceutical company’s stock after purchasing an additional 1,240 shares during the quarter. Granite Investment Partners LLC’s holdings in Celgene were worth $525,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Ayalon Holdings Ltd. bought a new stake in shares of Celgene in the second quarter valued at about $100,000. Atlantic Trust LLC bought a new stake in shares of Celgene in the second quarter valued at about $101,000. Moneta Group Investment Advisors LLC raised its holdings in shares of Celgene by 2,688.6% in the second quarter. Moneta Group Investment Advisors LLC now owns 10,290 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 9,921 shares in the last quarter. Harvest Fund Management Co. Ltd bought a new stake in shares of Celgene in the third quarter valued at about $132,000. Finally, City Holding Co. bought a new stake in shares of Celgene in the second quarter valued at about $143,000. Institutional investors and hedge funds own 73.87% of the company’s stock.

Several research firms recently weighed in on CELG. Zacks Investment Research upgraded Celgene from a “sell” rating to a “strong-buy” rating and set a $102.00 price objective for the company in a report on Wednesday, August 1st. Mizuho restated a “buy” rating and issued a $129.00 price objective on shares of Celgene in a report on Tuesday, July 31st. Cantor Fitzgerald assumed coverage on Celgene in a research note on Monday, October 1st. They issued an “overweight” rating and a $100.00 target price on the stock. BidaskClub upgraded Celgene from a “hold” rating to a “buy” rating in a research note on Thursday, August 16th. Finally, Morgan Stanley lifted their target price on Celgene from $91.00 to $93.00 and gave the company an “equal weight” rating in a research note on Friday, July 27th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $116.99.

Shares of CELG stock opened at $66.75 on Wednesday. Celgene Co. has a fifty-two week low of $66.63 and a fifty-two week high of $110.81. The stock has a market cap of $48.53 billion, a PE ratio of 9.76, a price-to-earnings-growth ratio of 0.43 and a beta of 1.53. The company has a debt-to-equity ratio of 4.06, a quick ratio of 1.99 and a current ratio of 2.13.

Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.02 by $0.27. Celgene had a return on equity of 108.76% and a net margin of 19.64%. The business had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.83 billion. Sell-side analysts predict that Celgene Co. will post 7.45 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/11/21/celgene-co-celg-shares-bought-by-granite-investment-partners-llc.html.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Story: What is a stock split?

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.